Clessidra, Avista Said to Buy Half of Italy’s Rottapharm

Rottapharm Madaus, a family-owned Italian drugmaker, agreed to sell a 50 percent stake to private equity firms Clessidra Capital Partners and Avista Capital Partners in a deal that values the company at about 1.7 billion euros ($2.2 billion), people with knowledge of the sale said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.